GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)

计划入组 110 人 · 首次发布于 2022 年 5 月 2 日

Telecoached Exercise Intervention for Connectivity Enhancement in Small Vessel Disease (TELECONNECT-SVD)

计划入组 60 人 · 首次发布于 2024 年 7 月 29 日

Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma

计划入组 75 人 · 首次发布于 2023 年 7 月 20 日

SVD2 (Susavion)

Beremagene geperpavec(Vyjuvek)

SVF

SVR GROUP

France

SPD DEVELOPMENT COMPANY LIMITED

United Kingdom

CENTRE HOSPITALIER SUD FRANCILIEN

France

Selinexor Approved in South Korea for Relapsed/Refractory Multiple Myeloma

Selinexor Triplet Therapy Shows Significant Survival Benefit in PI-Naive Multiple Myeloma Patients

Selinexor Shows Significant Survival Benefits in Multiple Myeloma Subgroups from BOSTON Trial